Table 3.
Study B, baseline characteristics of the 3 groups
| Measure and category | Progressor & Linear (n=352) | Progressor & Nonlinear (n=58) | Non progressor (n=25) | P |
|---|---|---|---|---|
| Sex | 0.3 | |||
| Male | 168 (47.7%) | 34 (58.6%) | 14 (56.0%) | |
| Female | 184 (52.3%) | 24 (41.4%) | 11 (44.0%) | |
| PKD genotype | 0.06 | |||
| NMD | 15 (4.4%) | 4 (7.0%) | 4 (16.7%) | |
| PKD1 | 279 (82.5%) | 42 (73.7%) | 16 (66.7%) | |
| PKD2 | 44 (13.0%) | 11 (19.3%) | 4 (16.7%) | |
| Previous use of any ARB at screening | 86 (24.8%) | 14 (24.1%) | 4 (16.0%) | 0.7 |
| Previous use of any ACEi at screening | 200 (57.6%) | 28 (48.3%) | 15 (60.0%) | 0.4 |
| Drug group | 0.3 | |||
| Lisinopril/Telmisartan | 166 (47.2%) | 32 (55.2%) | 15 (60.0%) | |
| Lisinopril/Placebo | 186 (52.8%) | 26 (44.8%) | 10 (40.0%) | |
| Family history of ADPKD | 314 (89.2%) | 51 (87.9%) | 19 (76.0%) | 0.1 |
| Hematuria in past 6 mo | 10 (2.8%) | 1 (1.8%) | 1 (4.0%) | 0.7 |
| Smoking history | 0.3 | |||
| Never | 218 (63.2%) | 33 (57.9%) | 12 (48.0%) | |
| Former | 101 (29.3%) | 18 (31.6%) | 12 (48.0%) | |
| Current | 26 (7.5%) | 6 (10.5%) | 1 (4.0%) | |
| Age at baseline (years) | 49.0 ± 7.9 | 47.4 ± 9.3 | 53.3 ± 7.9 | 0.01 |
| Age at diagnosis of ADPKD, y | 33.0 ± 12.3 | 33.3 ± 11.7 | 38.4 ± 13.5 | 0.1 |
| Age at diagnosis of HTN, y | 36.7 ± 10.0 | 35.7 ± 9.9 | 40.0 ± 11.9 | 0.2 |
| Home average SBP (mmHg) | 124.4 ± 10.6 | 125.3 ± 11.0 | 124.7 ± 14.2 | 0.9 |
| Home average DBP (mmHg) | 81.4 ± 8.0 | 83.3 ± 9.4 | 81.0 ± 8.7 | 0.4 |
| eGFR (ml/min/1.73 m2) | 48.1 ± 11.3 | 49.6 ± 13.4 | 53.4 ± 10.6 | 0.07 |
| Urine aldosterone (μg/24 h) | 9.5 ± 6.7 | 9.3 ± 5.8 | 10.3 ± 6.5 | 0.7* |
| Urine albumin (mg/24 h) | 30.0 [17.6–78.0] | 32.9 [15.6–85.2] | 20.0 [12.3–42.3] | 0.08* |
| BMI (kg/m2) | 27.8 ± 5.3 | 28.8 ± 5.2 | 27.5 ± 5.3 | 0.4 |
| Weight (kg) | 83.7 ± 19.8 | 87.5 ± 17.5 | 82.8 ± 18.4 | 0.4 |
| urinary creatinine excretion (mg/24 h) | 1425.4 ± 624.2 | 1510.2 ± 666.8 | 1702.3 ε ± 725.9 | 0.08 |
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range].
p value from log transformed variable
2 subjects had initial 24-hour creatinine excretion of 3.5 and 3.8 g/24 h with sodium excretion of 309 and 520 mmol/24 h, therefore these were likely significant over-collections; the 2 subjects did not report taking any dietary creatine-containing supplements. Excluding those 2 subjects from the nonprogressor analysis shows an initial creatinine excretion of 1535 ± 452 mg/24 h.
ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; BP: blood pressure; DBP, diastolic BP; eGFR: estimated glomerular filtration rate (using Chronic Kidney Disease Epidemiology Collaboration creatinine equation); HTN: hypertension; NMD: no mutation detected; PKD, polycystic kidney disease; SBP, systolic BP; TKV: total kidney volume.